Using a derivation cohort (N ¼ 349), we developed the first warfarin dosing algorithm that includes recently discovered polymorphisms in VKORC1 and CYP2C9 associated with warfarin dose requirement in African Americans (AAs). We tested our novel algorithm in an independent cohort of 129 AAs and compared the dose prediction to the International Warfarin Pharmacogenetics Consortium (IWPC) dosing algorithms. Our algorithm explains more of the phenotypic variation (R 2 ¼ 0.27) than the IWPC pharmacogenomics (R 2 ¼ 0.15) or clinical (R 2 ¼ 0.16) algorithms. Among high-dose patients, our algorithm predicted a higher proportion of patients within 20% of stable warfarin dose (45% vs 29% and 2% in the IWPC pharmacogenomics and clinical algorithms, respectively). In contrast to our novel algorithm, a significant inverse correlation between predicted dose and percent West African ancestry was observed for the IWPC pharmacogenomics algorithm among patients requiring X60 mg per week (b ¼ À 2.04, P ¼ 0.02).
INTRODUCTION
Warfarin is the most widely used anticoagulant with over 33 million prescriptions dispensed in the United States during 2011. 1 Although new oral anticoagulant drugs, such as dabigatran and rivaroxaban, were expected to supplant warfarin, 2,3 their use remains limited by cost, narrow indications, non-reversibility, gastrointestinal side effects, difficulty in monitoring anticoagulation and concerns about serious bleeding. 4, 5 Unfortunately, warfarin ranks among the top ten drug-related causes of serious adverse effects ranging from occult bleeding to death. 6 Although several polymorphisms have been found to be associated, the most well-studied genetic variants are CPY2C9*2 (rs1799853), CYPC9*3 (rs1057910) and VKORC1-1639 (rs9923231). 7 These genetic variants have been used by many groups, with the largest effort to date by the International Warfarin Pharmacogenetics Consortium (IWPC), to develop pharmacogenomics-guided warfarin dosing algorithms, which also include non-genetic factors in order to predict stable warfarin maintenance dose. 8, 9 The two, publicly available algorithms to predict dose response-the IWPC pharmacogenomics algorithm and the IWPC clinical algorithm-have been investigated for the predictive power in a large cohort. 9 However, the representation of African Americans (AAs) in this effort was low (o10% of the study population). 9 Most pharmacogenomics algorithms (developed largely in Caucasian populations) have been predominantly associated with warfarin sensitivity and, consequently, are more useful in identifying subgroups of patients who require low doses of warfarin. Furthermore, the minor allele frequencies of rs1799853, rs1057910 and rs9923231 variants are much lower among AAs compared with that in Caucasians. This may explain why these algorithms have shown more promise in Caucasian and Asian populations, predicting B55% of the variability in warfarin dose, given these two groups require lower doses of warfarin than populations of African descent. In fact, their ability to predict warfarin dose variability in AAs has been much lower, at B20%. 8, [10] [11] [12] Populations of recent African descent have a great amount of genetic diversity, much of which is specific to this population. 13 Consequently, single-nucleotide polymorphisms (SNPs) identified in Caucasian populations may not completely capture the genetic variation contributing to a phenotype in AAs.
Previously, we described two novel variants in VKORC1 (rs61162043) and in CYP2C9 (rs7089580) found through targeted resequencing efforts in AAs that were significantly associated with warfarin dose requirement independent of known genetic variants (rs9923231, rs1799853, rs1057910, rs28371686, rs7900194 and rs28371685).
14 More importantly, rs61162043 and rs7089580 were predictive of higher warfarin dose requirement in both the discovery and validation cohorts of AA patients on stable warfarin dose.
14 Through a large genome-wide association study (GWAS) in collaboration with the IWPC, we identified rs12777823, located upstream of CYP2C18, to be associated with lower warfarin dose requirement in AAs independent of rs1799853, rs1057910 and rs992323. 15 In addition, no significant association was found in European and Japanese GWAS data sets. individuals (previously described).
14 In this study, we determined whether our novel AA algorithm was significantly better at predicting the maintenance dose of warfarin than the IWPC's pharmacogenomics and clinical algorithms in an additional independent validation cohort of 149 AAs. Because of substantial variation of admixture rates among AAs, we also examined the association between percent West African ancestry (WAA) and warfarin dose prediction. 16 
MATERIALS AND METHODS
The study design included retrospective data from the derivation cohort (N ¼ 349) to generate our novel AA algorithm that was then tested in the validation cohort (N ¼ 149). 14 
Validation cohort
A total of 149 warfarin patients were recruited from anti-coagulation clinics at The University of Chicago, the University of Illinois at Chicago, The George Washington University Medical Faculty Associates, and the Veterans Affairs Hospital in Washington, DC. This validation cohort was independent of the derivation cohort from which the algorithm was generated. Inclusion criteria were patients self-described as AA, ageX18 years and treatment with a stable dose of warfarin, defined as the same dose for at least three consecutive clinic visits that produced an international normalized ratio (INR) within the therapeutic range. INR measurements for patients were made on a ProtTime Microcoagulation System (ITC, Edison, NJ, USA) or on Diagnostica Stago analyzers (STA-R Evolution and STA-Compact; Diagnostica Stago, Parsippany, NJ, USA). One 10-ml blood sample was taken from each subject by venipuncture, placed in purple-top Vacutainer tubes containing EDTA, and frozen at À 20 1C for DNA extraction. All protocols were approved by the institutional review boards from each participating institution. All patients provided written informed consent.
Genotyping
Genomic DNA was isolated from whole-blood samples using the Puregene (Gentra Biosystems, Germantown, MD, USA) DNA isolation kit. Patients were genotyped for rs1799853, rs1057910, rs28371686, rs7900194, rs28371685, rs9923231, rs61162043, rs7089580 and rs12777823 using previously published methods. 14, 17, 18 A panel of 105 ancestry informative markers (AIMs) was genotyped for each patient to determine WAA. 19 Genotyping of AIMs was performed with the MassArray 7K HT genetic analysis system (Sequenom, San Diego, CA, USA) as previously described. 20 SNPs out of Hardy-Weinberg equilibrium at Po0.001 and a call rate of o95% were excluded. Samples with SNP call rates o90% across all SNPs were excluded.
Statistical analysis
Deviations from Hardy-Weinberg equilibrium were evaluated using the Fisher's exact test in PLINK. 21 Global individual ancestry was determined for each study participant using AIMs for European and WAA. 19 Individual ancestry estimates were obtained from STRUCTURE 2.3.3 as previously described. 22 For each algorithm, the predicted dose of warfarin was correlated with the observed dose by the Pearson's correlation coefficient (r). Paired sample t-test was used to compare predicted mean dose for each algorithm with the observed dose. To evaluate the clinical accuracy of each algorithm, patients whose predicted dose fell within 20% of the actual stable therapeutic dose were divided into three dosing ranges according to the observed weekly dose: low dose (o40 mg per week), intermediate (40-50 mg per week) and high (450 mg per week).
The predictive accuracy was assessed by calculating the percentage of patients correctly assigned to each dosing group for all algorithms. Accuracy of each algorithm was assessed using the mean absolute error (MAE). A two-tailed P-value was computed using McNemar's test to determine whether the difference between two models was significant. To estimate the number of patients needed to genotype to prevent one adverse event, we used the methods previously described and as shown in Table 4 . 9, 23 The number of patients needed to genotype is the inverse of the absolute risk reduction, calculated as the absolute difference between the event rates for our novel AA algorithm and the IWPC clinical algorithm.
Statistical analysis was carried out using IBM SPSS Statistics version 19.0.0 package (SPSS, Chicago, IL, USA).
Algorithm generation
Our pharmacogenomics dosing model was generated using clinical and genotyping retrospective data from a derivation cohort of 349 AA patients and multivariate regression analysis.
14 Weekly warfarin dose was log 2 -transformed before statistical modeling to achieve an approximately normal distribution and was used as the dependent variable. The P-and bvalues are provided, reflecting the significance and the adjusted relative weight, respectively, of each variable included in the model ( Table 1) 
RESULTS
Patients with incomplete clinical or genotypic data required to run any of the algorithms were excluded. This resulted in 129 patients remaining in the analysis. Demographic, clinical and genetic variables for all study participants in the validation cohort are summarized in Table 2 . The mean therapeutic warfarin dose was 46.9 mg per week (s.d.±17.2), and more than half of our patients (59.7%) were started on warfarin due to DVT/PE. We combined rs1799853, rs1057910, rs28371686, rs7900194, rs28371685, (CYP2C9*2, *3, *5, *8 and *11) into a CYP2C9 star variant group due to low frequency of the individual SNPs, each of which reduces CYP2C9 activity. 14, 24 None of the SNPs showed deviations from Hardy-Weinberg equilibrium at Po0.001. The minor allele frequencies for rs1799853, rs1057910 and rs9923231 were low (0.02, 0.02 and 0.06, respectively), consistent with previous studies. 10, 14, 24 We tested the accuracy of the three algorithms in our AA validation cohort by comparing the predicted dose requirements with the actual maintenance dose for each patient. Comparisons of our novel AA algorithm to the IWPC algorithms are shown in Table 3 . The mean predicted dose using our novel AA algorithm was much closer to the actual mean therapeutic dose (47.6 and 46.9 mg per week, respectively), and the difference between the mean predicted dose and mean therapeutic dose was not significant (P ¼ 0.76). The predicted mean doses for the IWPC pharmacogenomics and clinical algorithms were found to be significantly lower (P ¼ 0.004 and P ¼ 3.3 Â 10 À 22 , respectively) than the mean therapeutic dose (Table 3) . Furthermore, the MAE with the novel AA algorithm (10.9 (s.e.±0.92)) was lower than the IWPC pharmacogenomics and clinical algorithms (12.2 (s.e.±0.98) and 17.9 (s.e. ± 1.2) mg per week, respectively). We found the correlation between the observed and the predicted dose was strongest for the novel AA algorithm (r ¼ 0.51) and the proportion of variability in warfarin dosage explained by the variables included in the algorithm was the highest (R 2 ¼ 0.27). The correlation between the predicted and observed doses for both the IWPC pharmacogenomics and clinical algorithms were similar (0.38 and 0.41, respectively), as well as the proportion of variability explained (R 2 ¼ 0.15 and 0.16, respectively), consistent with the findings by the IWPC in their AA cohort (R 2 ¼ 0.19). 9 Both the IWPC algorithms tended to underpredict warfarin doses, whereas the novel AA algorithm overpredicted doses (Figure 1 ). However, B38% of warfarin doses that were overpredicted by the novel AA algorithm were below 10 mg per week (Figure 1a) . Although the IWPC pharmacogenomics algorithm over-or underpredicted warfarin doses by up to 10 mg per week in B53% of patients (Figure 1b) , the IWPC clinical algorithm underpredicted warfarin doses for the majority of patients (86.8%), with 33% being underestimated by 10-20 mg per week (Figure 1c ). Our novel AA algorithm was able to predict the exact therapeutic dose in 10.9% of patients compared with 2.3% (P ¼ 0.02) and none for the IWPC pharmacogenomics and clinical algorithms, respectively (Table 3 and Figure 1 ). Previous warfarin algorithms have used the target prediction range of within 20% of the observed dose to assess algorithm performance. 9 We found that nearly 60% of predicted doses from our novel AA algorithm were within this 20% range compared with 48.8% and 26.4% for the IWPC pharmacogenomics and clinical algorithms, respectively ( Table 3) .
Most of the patients who are incorrectly dosed when using standard initiation doses require low or high warfarin doses; therefore, it is important to analyze the performance of the algorithms in the extreme-dose subgroups.
9,25 Hence, we examined the predictive accuracy of the novel AA algorithm for patients requiring low (o40 mg per week), intermediate (40- Figure 2 ). For patients requiring low doses, all three algorithms demonstrate similar predictive power. However, the MAE was lowest for the novel AA algorithm at 3.0 mg per week (s.e. ± 0.48) compared with the IWPC pharmacogenomics (3.8 mg per week, s.e. ± 0.58) and clinical algorithms (3.8 mg per week, s.e.±0.45). Among patients in the intermediate-dose group, the novel AA algorithm and the IWPC pharmacogenomics algorithm performed similarly with 82% and 84% of predicted doses within the 20% range, respectively, whereas the performance of the IWPC clinical algorithm begins to drop drastically with only 15.8% of warfarin doses predicted within the same range (Figure 2 ). For patients in the high-dose group, the novel AA algorithm significantly outperforms both the IWPC algorithms (Figure 2) . We found the novel AA algorithm was able to correctly detect the greatest percentage of high-dose patients (53%), whereas the IWPC pharmacogenomics and clinical algorithms correctly assigned 26% and 2%, respectively, of patients in this group. Overall, predicted doses derived from the novel AA algorithm were closer to the observed doses for more patients, and the precision was higher as demonstrated by the consistently lower MAE. To determine the clinical benefit of incorporating our novel AA algorithm into practice versus that using the IWPC clinical algorithm, we computed the number of patients needed to genotype. In order to prevent one predicted dose from being outside of the 20% therapeutic dose range (event), it was estimated that approximately three patients would need to be genotyped (Table 4) .
Self-reported race for AAs is not a strong proxy for genetic background and the availability of AIMs has made it possible to 26-29 Therefore, we examined how well our novel AA algorithm performs given the broad range of WAA among AAs. 30 Overall, among the doses predicted within a 20% range, mean percent WAA was not significantly different between the algorithms. For the IWPC pharmacogenomics algorithm, however, linear regression analysis revealed a strong inverse correlation between percent WAA and predicted dose within the 20% therapeutic dose range for patients requiring doses X60 mg per week (b ¼ À 2.04, P ¼ 0.02; Table 5 ). The correlation is also higher compared with our novel AA algorithm (r ¼ 0.41 and r ¼ 0.25, respectively). As expected, our novel AA algorithm did not show association, because populationspecific variables are incorporated and therefore may account for WAA.
DISCUSSION
In this study, a novel warfarin dose-prediction algorithm is presented and compared to the IWPC's clinical and pharmacogenomics algorithms for maintenance dose prediction in AAs. Our novel AA pharmacogenomics algorithm incorporates clinical and genetic information found to be specifically associated with warfarin dose in AAs, resulting in a much higher percentage of predicted doses within 20% of the observed dose, decreased MAE in the predicted dose estimates, increased fraction of variability explained by these factors (R 2 ) and a predictive power that is sensitive to within population diversity. The integration of novel SNPs associated with increased weekly warfarin dose in AAs also improves the accuracy of warfarin dose prediction in AA patients under high-dose regimens. One critical clinical factor that is taken into account by our algorithm is the presence of DVT/PE, for which AAs have the highest incidence and mortality rates in the United Stares. 31, 32 These results suggest that incorporation of our AA ). Number of patients in each dose group is shown at the bottom. Table 3 ). This significant improvement in dose prediction was more pronounced among patients whose stable therapeutic dose was 450 mg per week. This is clinically relevant, as these patients are the most at-risk patients for adverse consequences of warfarin initiation from underdosing and may demonstrate the greatest benefit from pharmacogenomics dosing. We found the number of patients needed to genotype was 3.07 when comparing our novel AA algorithm with the IWPC clinical algorithm. Meaning, one misclassification is avoided for approximately every three patients whose dose is estimated using our novel AA algorithm when compared with that using the IWPC clinical algorithm. This estimate is much lower than the comparison of the IWPC pharmacogenomics algorithm with the IWPC clinical algorithm at 13.2. 9 Recently, a clinical study has shown that genotypeguided warfarin dosing better predicted warfarin maintenance dose and reduced out-of-range INRs compared with that by standard dosing. 33 However, clinical implementation of pharmacogenomic algorithms is, in part, hindered by the time and the cost required to obtain genotypes utilizing traditional methods. This may be overcome through progress in genotyping technologies, such as rapid-melting curve analysis, which can provide results within 1 h. 34 With the drop in cost of genotying, we forsee the development of population-specific panels of variants to become feasible. A model system designed to overcome many of the barriers associated with the translation of pharmacogenomics into clinical practice (The 1200 Patient Project) was recently implemented, where the use of pre-emptive genotyping for a large number of variants reduces cost (o$500 per patient) and an interactive informatics portal aims to improve the interpretation of results into clinical action. 35 A study evaluated the performance of nine algorithms, including the IWPC pharmacogenomics algorithm, by race and found the MAE to be the highest in the AA population compared with that of Caucasians and Asians. 36 They found the IWPC pharmacogenomics algorithm to perform better for AAs. They obtained similar results for their AA cohort as we did for our cohort when utilizing the IWPC pharmacogenomics algorithm (MAE ¼ 12.0 mg per week, within 20% ¼ 46.4%; MAE ¼ 12.2 mg per week, within 20% ¼ 48.8%, respectively). 36 Recently, Ramirez et al. 37 proposed an 'expanded genetic algorithm,' which included CYP4F2 and CALU variants not used in our novel algorithm that predicted warfarin dose better in AAs and European Americans compared with IWPC's. However, this expanded algorithm only predicted correctly the low dose for AAs in 3 out of 12 cases compared with our novel AA algorithm where 21 individuals out of 46 were correctly assigned ( Figure 2) . 37 As for the high-dose group, their expanded algorithm performed similarly to the IWPC's algorithm, 37 whereas our novel algorithm correctly detected 27% and 51% more individuals requiring high doses compared with the IWPC pharmacogenomics and clinical algorithms, respectively.
There are limitations in our study, such as the exclusion of other genetic variants and clinical factors that have been shown to be associated with warfarin dose requirements. One study found rs339097 in CALU to be associated with high warfarin doses in AAs; 38 however, in our derivation cohort we did not observe this association 14 and, consequently, the SNP was excluded from our algorithm. SNPs rs7089580 and rs12777823 were not statistically significant in our initial multivariate regression analysis, but were included because of their significant association in our univariate analysis and previous strong association to warfarin dose requirement in AAs in larger population cohorts. 14, 15 In the univariate analysis on the derivation cohort, rs1799853 was marginally significant (P ¼ 0.047) and rs1057910 was not statistically significant (P ¼ 0.11).
14 The mean warfarin dose is considered high, which may lead to a bias in algorithm performance. However, the mean warfarin dose in our cohort is similar to that in other published studies among AAs and, therefore, represents typical doses in this population. In fact, AA ethnicity has been found to be a predictor of warfarin doses X5 mg per day. 39 Although, we have not assessed our novel algorithm's performance in other ethnicities, the incorporation of SNPs rs61162043, rs7089580 and rs12777823, which are associated with warfarin dose response among AAs, as well as clinical factors found to be more prevalent among AAs (DVT/PE, higher dose requirement), can potentially hinder its performance in other ethnic groups. Another limitation is our sample size for the validation cohort. Nonetheless, given the scarcity of AA pharmacogenomics samples, our study is still one of the largest in this population.
As our novel AA algorithm incorporates several African-specific CYP2C9 star alleles, we can better account for the effect of decreased enzyme activity on warfarin dose in this population. Therefore, our algorithm continues to perform as well as the IWPC pharmacogenomics algorithm in the prediction of low warfarin dose requirement, further demonstrating the need for populationspecific algorithms. Studies have found that genetic ancestry proportions can vary significantly within individuals who selfidentify as the same racial group and, therefore, we utilized percent WAA as an assessment tool in algorithm predictability. 40, 41 This is important considering that AAs have a broad range of ancestry; for example, it has been shown that only 34% of AAs possess 490% WAA as opposed to 98% of EAs who have 490% European ancestry. 26 For the IWPC pharmacogenomics algorithm, we observed an inverse correlation between percent WAA and performance among high-dose patients ( Table 5 ). The loss of predictability found in IWPC pharmacogenomics algorithm suggests that non-population-specific algorithms lose predictability after certain genetic variance thresholds between populations are exceeded. The identification and incorporation of populationspecific alleles into population-specific pharmacogenomics algorithm can simultaneously take into account genetic ancestry and help optimize warfarin doses. In addition, our findings strongly suggest that there may be other African-specific variants associated with warfarin dose requirement that have yet to be identified.
In conclusion, we have developed a novel pharmacogenomics dose algorithm that predicts the stable therapeutic dose of warfarin more effectively than either of the IWPC algorithms for AAs, and the predictive power was not affected by the percentage of WAA in patients. We have incorporated SNPs previously associated with warfarin dose requirements in AAs that have not been used in any other pharmacogenomics algorithm. By focusing on population-specific clinical and genetic variables, we were able to more accurately predict warfarin dose in AAs, with the potential to address an important source of health disparities in this pharmacogenetically underserved group.
